Gozewijn D Laverman Selected Research

Telmisartan (Micardis)

11/2023	Overall and inter-individual effect of four different drug classes on soluble urokinase plasminogen activator receptor in type 1 and type 2 diabetes.
10/2023	Effects of baricitinib, empagliflozin, linagliptin and telmisartan on cardiovascular autonomic neuropathy in type 1 diabetes: An exploratory, randomized, open-label, crossover trial.
1/2023	Optimization of Albuminuria-Lowering Treatment in Diabetes by Crossover Rotation to Four Different Drug Classes: A Randomized Crossover Trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Gozewijn D Laverman Research Topics

Disease

31	Type 2 Diabetes Mellitus (MODY) 12/2023 - 05/2012
16	Chronic Renal Insufficiency 01/2023 - 09/2003
16	Proteinuria 01/2021 - 09/2002
12	Albuminuria 10/2020 - 06/2011
11	Diabetic Nephropathies (Diabetic Nephropathy) 01/2021 - 07/2011
4	Hypertension (High Blood Pressure) 01/2020 - 12/2011
4	Nephrosis 02/2013 - 01/2003
3	Body Weight (Weight, Body) 01/2022 - 03/2012
3	Cardiovascular Diseases (Cardiovascular Disease) 10/2020 - 01/2018
3	Inflammation (Inflammations) 10/2020 - 09/2011
2	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 10/2023 - 01/2023
2	Diabetes Mellitus 01/2020 - 01/2019
2	Kidney Diseases (Kidney Disease) 01/2020 - 11/2009
2	Vascular Calcification 09/2012 - 01/2012
2	Fibrosis (Cirrhosis) 09/2011 - 08/2011
1	Acute Kidney Injury (Acute Renal Failure) 11/2023
1	Sarcopenia 02/2022
1	Malnutrition (Nutritional Deficiencies) 02/2022
1	Autoimmune Diseases (Autoimmune Disease) 10/2021
1	Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis 10/2021
1	Vasculitis (Vasculitides) 10/2021
1	Hypoxia (Hypoxemia) 01/2020
1	Hyperglycemia 01/2020
1	Neoplasms (Cancer) 01/2020
1	Glycosuria 01/2019
1	Weight Loss (Weight Reduction) 01/2019
1	Coronary Disease (Coronary Heart Disease) 03/2018
1	Paralysis (Palsy) 04/2015
1	Renal Tubular Acidosis (Distal Renal Tubular Acidosis) 04/2015
1	Rapidly progressive glomerulonephritis with pulmonary hemorrhage 05/2014

Drug/Important Bio-Agent (IBA)

18	SodiumIBA 01/2022 - 01/2003
10	CreatinineIBA 11/2023 - 09/2002
10	AlbuminsIBA 11/2023 - 01/2016
10	dapagliflozinIBA 01/2023 - 10/2017
9	Glucose (Dextrose)FDA LinkGeneric 01/2023 - 10/2017
7	Proteins (Proteins, Gene)FDA Link 01/2022 - 12/2002
7	Dietary SodiumIBA 01/2020 - 12/2002
5	Biomarkers (Surrogate Marker)IBA 11/2023 - 10/2020
5	Dietary ProteinsIBA 02/2022 - 05/2019
5	Sodium-Glucose Transporter 2 InhibitorsIBA 01/2020 - 01/2018
5	Losartan (Cozaar)FDA LinkGeneric 01/2017 - 09/2002
4	Angiotensin Receptor AntagonistsIBA 11/2019 - 06/2011
4	Hydrochlorothiazide (Esidrix)FDA LinkGeneric 09/2019 - 08/2011
4	AldosteroneIBA 12/2017 - 03/2010
4	Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)IBA 04/2017 - 06/2003
4	Lisinopril (Prinivil)FDA LinkGeneric 01/2017 - 09/2002
4	DiureticsIBA 05/2014 - 12/2002
3	Fibroblast Growth Factor-23IBA 12/2023 - 11/2019
3	pro-brain natriuretic peptide (1-76)IBA 12/2023 - 03/2012
3	baricitinibIBA 11/2023 - 01/2023
3	Telmisartan (Micardis)FDA Link 11/2023 - 01/2023
3	LinagliptinIBA 11/2023 - 01/2023
3	empagliflozinIBA 11/2023 - 01/2023
3	DiamondIBA 01/2022 - 01/2020
3	LDL CholesterolIBA 01/2022 - 01/2018
3	SymportersIBA 01/2021 - 10/2017
3	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 11/2019 - 01/2016
3	Doxorubicin (Adriamycin)FDA LinkGeneric 09/2003 - 01/2003
2	alpha-2-HS-GlycoproteinIBA 11/2023 - 10/2023
2	PotassiumIBA 01/2023 - 04/2015
2	CadmiumIBA 01/2023 - 07/2020
2	CarbohydratesIBA 02/2022 - 01/2022
2	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2022 - 02/2013
2	Antineutrophil Cytoplasmic Antibodies (ANCA)IBA 10/2021 - 05/2014
2	Sodium-Glucose Transport ProteinsIBA 01/2020 - 01/2019
2	Phosphates (Orthophosphate)IBA 01/2020 - 01/2019
2	Hormones (Hormone)IBA 01/2020 - 01/2019
2	SaltsIBA 01/2019 - 03/2012
2	AngiotensinsIBA 01/2018 - 04/2017
2	ReninIBA 01/2018 - 04/2017
2	Calcitriol Receptors (Calcitriol Receptor)IBA 04/2017 - 01/2016
2	paricalcitol (Zemplar)FDA Link 04/2017 - 01/2016
2	Lipoproteins (Lipoprotein)IBA 02/2013 - 01/2006
2	Vitamin K FDA Link 09/2012 - 01/2012
2	Angiotensin Receptors (Angiotensin II Receptor)IBA 03/2012 - 07/2011
1	Urokinase Plasminogen Activator ReceptorsIBA 11/2023
1	Glycated Hemoglobin (Glycosylated Hemoglobin)IBA 07/2021
1	Insulin (Novolin)FDA Link 07/2021
1	DisaccharidesIBA 10/2020
1	Leukocyte L1 Antigen Complex (Calgranulin)IBA 10/2020
1	Spironolactone (Aldactone)FDA LinkGeneric 01/2020
1	Oxygen (Dioxygen)IBA 01/2020
1	Hypoglycemic Agents (Hypoglycemics)IBA 01/2020
1	IodineIBA 09/2019
1	Eplerenone (Inspra)FDA LinkGeneric 01/2019
1	aminoacyl-histidine dipeptidaseIBA 01/2019
1	Glucagon-Like Peptide 1 (GLP 1)IBA 01/2019
1	1-(2-chloroethyl)-1-nitrosourea (CNU)IBA 01/2019
1	MagnesiumIBA 03/2018
1	Dihydrotachysterol (AT 10)IBA 04/2017
1	Ramipril (Altace)FDA LinkGeneric 04/2017
1	5'-palmitoyl cytarabine (PLAC)IBA 04/2017
1	dirhodium tetraacetate (DRTA)IBA 04/2015
1	Myeloblastin (Proteinase 3)IBA 05/2014
1	goralatideIBA 12/2013
1	LDL Receptors (LDL Receptor)IBA 02/2013
1	Valsartan (Vals)FDA Link 02/2013

Therapy/Procedure

14	Therapeutics 01/2023 - 09/2002
3	Sodium-Restricted Diet (Diet, Sodium Restricted) 02/2013 - 07/2011
1	Diet Therapy (Therapy, Diet) 05/2014